Short Interest in Turnstone Biologics Corp. (NASDAQ:TSBX) Grows By 42.9%

Turnstone Biologics Corp. (NASDAQ:TSBX - Get Free Report) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 625,900 shares, an increase of 42.9% from the March 15th total of 438,000 shares. Based on an average daily volume of 181,300 shares, the short-interest ratio is presently 3.5 days. Approximately 4.7% of the shares of the stock are sold short.

Institutional Trading of Turnstone Biologics

Institutional investors and hedge funds have recently modified their holdings of the stock. Citigroup Inc. bought a new position in shares of Turnstone Biologics in the third quarter worth $30,000. Rhumbline Advisers purchased a new position in Turnstone Biologics in the 3rd quarter worth approximately $31,000. Charles Schwab Investment Management Inc. purchased a new stake in Turnstone Biologics during the 3rd quarter valued at $60,000. New York State Common Retirement Fund bought a new stake in shares of Turnstone Biologics during the 3rd quarter valued at $74,000. Finally, Northern Trust Corp bought a new stake in shares of Turnstone Biologics during the 3rd quarter valued at $228,000. 52.51% of the stock is owned by hedge funds and other institutional investors.

Turnstone Biologics Trading Down 5.6 %

TSBX stock traded down $0.19 during midday trading on Friday, reaching $3.19. 106,987 shares of the stock were exchanged, compared to its average volume of 181,235. The company has a fifty day moving average price of $3.10 and a 200 day moving average price of $2.79. Turnstone Biologics has a 52 week low of $1.63 and a 52 week high of $13.20.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas.